The British Columbia Ministry of Health is partnering with academic institutions to develop a custom gene-editing treatment for a three-year-old Surrey boy. Gurmoh suffers from a rare form of spastic paraplegia , and the initiative aims to create a broader system for treating rare genetic disorders.
The $2.7 million catalyst for B.C.'s new therapy pathway
The provincial government's decision to intervene follows an intense grassroots campaign by Gurmoh's parents, Stalin and Navpreet Gill. according to the reprt,the family and their community raised over $2.7 million through various fundraisers over five months to fund the creation of a personalized therapy. this effort included a high-profile walk from downtown Vancouver to the legislature in Victoria to draw attention to the plight of children with rare diseases.
The urgency of the situation is underscored by the progressive nature of Gurmoh's condition. Stalin Gill noted that when the family first contacted the Ministry of Health three months prior to their meeting with then-minister Josie Osborne, Gurmoh was able to climb stairs with significantly more ease than he can today. This timeline suggests that for neurodegenerative disorders, the gap between diagnosis and government action can be a critical window of lost mobility.
UBC and McGill's role in treating spastic paraplegia
To address the medical challenge, the Provincial Health Services Authority (PHSA) and BC Children's Hospital are collaborating with the University of British Columbia (UBC) and McGill University's Montreal Neurological Institute-Hospital, known as The Neuro. This partnership is designed to bridge the gap between identifying a genetic mutation and delivering a viable clinical treatment.
Gurmoh's condition is caused by a de novo mutation, meaning the genetic error was not inherited from either parent. As reported, this specific mutation often leads to severe early-onset symptoms, including progressive muscle stiffness, weakness in the legs, and speech difficulties, as it attacks the nerves in the spinal cord that regulate movement.
Turning genomic diagnosis into a clinical opportunity
This initiative represents a shift in how British Columbia handles rare genetic conditions. Dr. Federica Di Palma, the chief health genomic officer for the PHSA, stated that while genomic diagnosis is increasingly providing answers for children, the next hurdle is converting those answers into actual treatment opportunities. By linking the clinical care of BC Children's Hospital with the research capabilities of UBC and McGill,the province hopes to build a scalable system.
This move mirrors a global trend toward "n-of-1" therapies, where medicine is tailored to a single individual's unique genetic code. By establishing this "diagnosis-to-therapy pathway," Health Minister Ravi Kahlon intends for every diagnosis to serve as a starting point for treatment rather than a dead end,potentially benefiting both children and adults with rare diseases in the future.
The timeline for Gurmoh's first gene-editing dose
Despite the optimistic announcement, several critical details remain unknown. The Ministry of Health has not specified the exact timeline for when Gurmoh will receive the first dose of the personalized therapy, nor has it detailed the specific gene-editing technology—such as CRISPR or viral vectors—that will be employed. furthermore, the report does not clarify how the $2.7 million raised by the Gill family will be integrated with provincial funding or if the government will assume the long-term costs of the treatment's administration.
Comments 0